Prostat Adenokarsinomunda CD44 Ekspresyonu: Gleason Derecesi ile Korelasyon

Amaç: Bir yüzey adezyon proteini olan CD44, kök hücre belirteci olup prostat glandlarının bazal hücrelerinin yapısal bütünlüğünü korumada görev alır. Prostat karsinogenezisinde de önemli bir rolü olduğu düşünülse de şu ana dek yapılan çalışmalarda elde edilen sonuçlar belirsizdir. Bu çalışma, farklı Gleason büyüme patternlerine sahip tümörlerde ve hiperplastik glandlarda CD44 ekspresyonunu değerlendirmek amacı ile yapılmıştır.

Anahtar Kelimeler:

Prostat karsinogenezis, Kök Hücreler, Prostatik Hiperplazi, Keratinler

CD44 EXPRESSION IN PROSTATIC ADENOCARCINOMA: CORRELATION WITH GLEASON GRADES

Objective: CD44, a cell-surface adhesion protein, is a marker of stem cells and is involved in the structural maintenance of prostate gland basal cells. It plays an important role in prostate carcinogenesis; however, research results till date have been inconsistent. The current study was conducted to evaluate the expression level of CD44 among carcinomas with different Gleason growth patterns and hyperplastic glands.

Keywords:

Prostate Carcinogenesis, Stem cells, Prostatic Hyperplasia, Keratins,

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Crona DJ, Whang Y. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 2017;9(6):67.
3. Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64.
4. Harris KS, Kerr BA. Prostate cancer stem cell markers drive progression, therapeutic resistance, and bone metastasis. Stem Cells Int. 2017;(2):1-9.
5. Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, Madjd Z. Co-Expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res. 2017;23(4):793-802.
6. Mizukami T, Kamachi H, Mitsuhashi T, Tsuruga Y, Hatanaka Y, Kamiyama T et al. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy. BMC Cancer 2014;14:687.
7. Rich JN. Cancer stem cells: understanding tumor hierarchy and heterogeneity. Medicine (Baltimore). 2016;95(Suppl 1):S2-S7.
8. Zhao W, Li Y, Zhang X. Stemness-Related Markers in Cancer. Cancer Transl Med. 2017;3(3):87-95.
9. Wang Y, Hayward S, Cao M, Thayer K, Cunha G. Cell differentiation lineage in the prostate. Differentiation 2001;68(4):270-9.
10. Trompetter M, Smedts F, van der Wijk J, Schoots C, de Jong HJ, Hopman A et al. Keratin profiling in the developing human prostate. A different approach to understanding epithelial lineage. Anticancer Res 2008;28(1A):237-43.
11. Kwon O, Xin L. Prostate epithelial stem and progenitor cells. Am J Clin Exp Urol. 2014;2(3):209-18.
12. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004;64(16):5702-11.
13. Lokeshwar BL, Lokeshwar VB, Block NL. Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res 1995;15(4):1191-8.
14. Shang Z, Cai Q, Zhang M, Zhu S, Ma Y, Sun L et al. Switch from CD44+ cell to EMT cell drives the metastasis of prostate cancer. Oncotarget 2015;6(2):1202-16.
15. Verkaik NS, van Steenbrugge GJ, van Weerden WM, Bussemakers MJ, van der Kwast TH. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest 2000;80(8):1291-8.